Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Be1a23263129076d6ccfc93a585f6ec59> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Be1a23263129076d6ccfc93a585f6ec59 NCIT_P378 "NCI" @default.
- Be1a23263129076d6ccfc93a585f6ec59 type Axiom @default.
- Be1a23263129076d6ccfc93a585f6ec59 annotatedProperty IAO_0000115 @default.
- Be1a23263129076d6ccfc93a585f6ec59 annotatedSource NCIT_C158557 @default.
- Be1a23263129076d6ccfc93a585f6ec59 annotatedTarget "An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody botensilimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody." @default.